- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
SUO Annual Meeting | Conferences
Trials Demonstrate Which Treatments Physicians Should Use in EGFR+ NSCLC
December 14, 2020
Edgardo S. Santos Castillero, MD, reviewed the case of a 73-year-old Asian man who was diagnosed with stage IV EGFR-mutant non-small cell lung cancer and discussed the treatment options he would consider for this patient.
Jelmyto Induces Durable Responses in Patients With Low-Grade Upper Tract UC
December 05, 2020
Treatment with mitomycin-containing reverse thermal gel, led to complete responses in over 50% of patients with low-grade upper tract urothelial carcinoma, which were maintained at 1 year, final results from the pivotal phase 3 OLYMPUS trial show.
PSMA Radioligand Therapy Generates Excitement in Prostate Cancer Treatment Paradigm
December 04, 2020
Ulka Vaishampayan, MD, discusses the excitement surrounding PSMA radioligand therapy in the prostate cancer space.
Olaparib Treatment Leads to Significant Survival Improvement in Patients with mCRPC
December 04, 2020
A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.
Lower Risk of Death Observed With Enzalutamide in Patients with nmCRPC
December 04, 2020
Treatment with enzalutamide in combination with androgen deprivation therapy led to a clinically meaningful decrease in the risk of death for patients with non-metastatic castration resistance prostate cancer.
Understanding the Various Biomarker Settings for Metastatic Prostate Cancer
December 04, 2020
In a presentation during the 21st Annual Meeting of the Society of Urologic Oncology, Kara N. Maxwell, MD, PhD, expanded upon the available biomarkers for use in prostate cancer and how they can be applied at various points and for guiding toward which treatments can improve care of patients with prostate cancer.
Enzalutamide Shows PFS Benefit Across Subgroups of nmCRPC
December 03, 2020
Enzalutamide achieved both an improvement in progression-free survival and an increase in time to PSA progression compared with bicalutamide as treatment of patients with nonmetastatic castration-resistant prostate cancer.
Nadofaragene Firadenovec Demonstrates Continued Efficacy Across Subgroups in BCG-Unresponsive NMIBC
December 03, 2020
In a subgroup of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer, the novel intravesical gene-mediated therapy nadofaragene firadenovec maintained its efficacy, according to a poster shared during the 21st Annual Meeting of the Society of Urologic Oncology.
Exploring PSMA Therapies in Prostate Cancer
December 03, 2020
Declan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
HIF-2α Inhibition Warranted for VHL-Associated Clear Cell Renal Cell Carcinoma
December 03, 2020
The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.